NBIX vs TBI · P/E 45, rev $1.77B vs rev $841.6M
Neurocrine Biosciences Inc (NBIX) versus TrueBlue Inc (TBI) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
TrueBlue Inc (TBI) is a staffing & employment services company listed on NYSE.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported TBI revenue for 2026-06-28 was $841.6M. Net income was -$23.2M. TBI currently screens at market cap $205.8M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. TBI currently screens at market cap $205.8M.
Not investment advice. Open the NBIX and TBI stock pages for the full models.
Not investment advice.